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CASE PRESENTATION
A 47-year-old white man who worked as a professional musi-
cian presented to his general practitioner with a 3-week history
of malaise, loss of appetite, slight weight loss, and dark urine.
There was no history of respiratory symptoms and, in particu-
lar, no hemoptysis. He had had mild asthma for 10 years,
which had been treated with inhaled bronchodilators. He was
a lifelong nonsmoker and drank alcohol only occasionally. He
had no family history of renal disease.
The general practitioner detected proteinuria and hematu-
ria, and blood tests showed an elevated serum creatinine. The
patient was referred to our renal unit the same day. On arrival,
he looked well and was afebrile with no rash or edema. Pulse
was 80 beats/minute and regular, and blood pressure was 145/70
mm Hg. Clinical examination of the heart, lungs, abdomen,
and nervous system was normal. Urinalysis showed 2 blood,
3 protein, dysmorphic red cells, and granular and red cell
casts. Serum creatinine was 550 mol/L (6.3 mg/dL) and urea
21 mmol/L. Electrolytes were in the normal range, but albumin
was reduced at 2.3 g/dL. Blood picture showed hemoglobin
10.7 g/dL; white blood cell count 9.6  109/L; and platelets
654  109/L. Oxygen saturation with the patient breathing
room air was 94%, and a chest radiograph was normal.
An enzyme-linked immunosorbent assay (ELISA) for anti-
glomerular basement membrane (anti-GBM) antibodies was
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positive at 80% (normal range, 0% to 15%), confirmed by
positive binding on a Western blot using collagenase solubilized
human GBM. Anti-neutrophil cytoplasm antibodies (ANCA)
and anti-nuclear antibodies were negative, and complement
levels were normal. Renal biopsy disclosed a focal segmental
necrotizing glomerulonephritis in 17 of 27 glomeruli, with cellu-
lar crescents in most of them (Fig. 1A and B). In some glomer-
uli, there was rupture of Bowman’s capsule, with a giant cell
response. The interstitium contained a dense focal mononu-
clear cell infiltrate, and tubules had focal dedifferentiation with
many red cell casts. Immunoperoxidase studies showed strong
deposition of IgG in a linear pattern along the GBM, with
weaker staining for IgM and C3 (Fig. 1C). The conclusion was
that the biopsy revealed crescentic glomerulonephritis due to
anti-GBM disease.
Treatment was started with oral prednisolone, 60 mg daily,
and cyclophosphamide, 200 mg daily. Plasma exchange was
performed daily for 14 days using 4 L exchanges for human
albumin, with 500 mL fresh frozen plasma for 5 days following
renal biopsy. The patient showed a good response to treatment.
Anti-GBM antibodies fell to within the normal range by 2
weeks. His urine output increased rapidly to more than 2 L per
day, and the serum creatinine slowly improved. He developed
transient neutropenia at 3 weeks, which improved on discontin-
uation of cyclophosphamide for 7 days. No other adverse ef-
fects of treatment occurred. Cyclophosphamide was stopped
after 3 months, and prednisolone was rapidly tapered by 3
months and discontinued by 6 months. Anti-GBM antibodies
remained negative, and the serum creatinine fell to 180 mol/L
(2.0 mg/dL).
At last follow-up, after 3 years, the patient was well, and his
serum creatinine had improved to 152 mol/L (1.7 mg/dL).
Urinalysis still showed small amounts of blood and protein.
He was taking antihypertensive medication only.
DISCUSSION
Prof. Charles D. Pusey (Renal Section, Division of
Medicine, Imperial College London; and Hammersmith
Hospital, London, United Kingdom): The patient pre-
sented illustrates the difficulty in making an early diagno-
sis of anti-GBM disease when only the kidney is involved.
More important, this case demonstrates that patients
with advanced renal failure can recover independent re-
nal function if treated aggressively. The term “anti-GBM
disease” is now widely used to describe patients in whom
anti-GBM antibodies are associated with crescentic
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Fig. 1. (A ) Low-power view of renal biopsy showing several cellular
crescents at the same stage of evolution. There is dense interstitial
infiltration with mononuclear cells (silver methenamine 100). (B )
High-power view of a glomerulus showing fibrinoid necrosis, breaks in
the basement membrane, and crescent formation. Bowman’s capsule
is disrupted and there is periglomerular inflammation (silver methena-
mine 200). (C ) Immunohistology demonstrating linear deposition of
IgG on the basement membrane in a glomerulus with a large crescent
(immunoperoxidase 200). Courtesy of Professor Terry Cook.
glomerulonephritis [1, 2], often in association with alveolar
hemorrhage, and rarely with other clinical features such
as retinopathy. Occasionally, patients present with pul-
monary hemorrhage alone, without overt renal disease,
although urinary abnormalities may be present and glo-
merular deposits of anti-GBM antibodies are often found
if renal biopsy is performed. Anti-GBM disease is re-
garded by some as a specific and restricted form of sys-
temic vasculitis, which affects only the capillary beds of
selected organs containing the target auto-antigen. This
auto-antigen has been identified as the 3 chain of type
IV collagen.
Anti-GBM disease is also known as “Goodpasture’s
disease” or “Goodpasture’s syndrome” [3, 4]. Briefly,
the term Goodpasture’s syndrome was first used in the
1950s by Stanton and Tange [5], who described a series
of patients with pulmonary-renal syndrome, similar to
the patient first reported by Goodpasture in 1919 [6]. It is
not known whether these cases, or indeed Goodpasture’s
original case, had anti-GBM antibodies, because tech-
niques for detecting them were not available at the time.
The presence of antibodies to the GBM was first demon-
strated in the 1960s, following the development of immu-
nofluorescence techniques for use in renal biopsies [7, 8].
Some authors now use the term Goodpasture’s syn-
drome to describe the combination of severe glomerulo-
nephritis and lung hemorrhage, as it was originally used,
regardless of etiology. Others reserve this diagnosis for
cases in which anti-GBM antibodies also have been de-
tected. For simplicity, I think that the term anti-GBM
disease has some merit, and I will use this synonymously
with Goodpasture’s disease to describe patients with
anti-GBM antibodies accompanied by kidney and/or
lung involvement.
Clinical features
The clinical features of anti-GBM disease have been
reviewed recently [2, 3, 9] so I shall only summarize them
briefly. There is a bimodal age distribution, with peak
incidence in the third and sixth decades, and a slight
overall excess of males. Most patients present with the
combination of rapidly progressive glomerulonephritis
and lung hemorrhage, although 30% to 40% present
with isolated renal involvement. Renal disease can pres-
ent with hematuria, accompanied by mild to moderate
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proteinuria, with “acute nephritis,” or with features of
acute renal failure. Hypertension is usually a late feature,
accompanying advanced renal failure and fluid retention.
Lung disease, which is commoner in young men, presents
with breathlessness and cough, sometimes accompanied
by overt hemoptysis. Chest radiographs can reveal alveo-
lar shadowing, but this appearance is nonspecific, and a
more sensitive test is the corrected carbon monoxide
transfer factor (KCO) [10]. Many patients also develop
systemic features such as malaise, fatigue, and weight
loss, and these might relate to anemia from pulmonary
hemorrhage or to the effects of uremia. Additional clini-
cal features, such as arthralgia and myalgia, have been
reported, but it is difficult to know whether these in fact
represent manifestations of an accompanying ANCA-
positive systemic vasculitis.
Anti-GBM disease is a rare disorder with an incidence
estimated at around one patient per million population.
However, it might be responsible for up to 20% of cases
of rapidly progressive glomerulonephritis. The disease
is commoner in white populations and appears to be
very rare in those of African origin. Although some
have suggested that the incidence of anti-GBM disease
is higher in spring and early summer, this is not the
case in all series. There are some reports of localized
“outbreaks” of the disease, possibly suggesting a rela-
tionship with infection. The commonest disease associa-
tion is with ANCA-positive systemic vasculitis: ANCA
are found in approximately 30% of patients with anti-
GBM disease, and 5% to 10% of patients presenting
with ANCA-positive systemic vasculitis have anti-GBM
antibodies [11]. Occasionally, patients with membranous
nephropathy develop crescentic glomerulonephritis in
association with anti-GBM antibodies. Associations with
urinary tract obstruction and with lithotripsy for ureteric
calculi also have been reported. Patients with Alport’s
syndrome can develop anti-GBM disease in the allograft
following renal transplantation.
Laboratory features
Almost all patients with Goodpasture’s disease have
circulating anti-GBM antibodies detectable by ELISA.
Most of the available assays use purified bovine or sheep
GBM enriched for the NC1 domain of the 3 chain of
type IV collagen [3(IV)NC1]. Although such assays
are highly specific and sensitive, we confirm all positive
results by Western blotting on collagenase-solubilized
human GBM. Rarely, these standard assays are negative
despite the presence of deposited anti-GBM antibodies
in the kidney. We have found that low levels of circulat-
ing anti-GBM antibody can be detected in the serum
of such patients using a sensitive biosensor assay [12].
Biosensors incorporating chips coated with recombinant
3(IV)NC1 are likely to be more widely used in the
future.
In the correct clinical context, positivity in well-estab-
lished assays can be used as an indication to start treat-
ment when renal biopsy cannot be performed immedi-
ately. However, we prefer to perform renal biopsy in all
patients who have evidence of renal involvement. We
then can perform immunofluorescence studies and can
assess the extent and activity of glomerulonephritis by
light microscopy. Almost all specimens have linear de-
posits of IgG along the GBM, often accompanied by
complement C3, and occasionally by other immunoglob-
ulin isotypes, such as IgA and IgM. Light microscopy
generally reveals widespread crescent formation. The
disease is typically monophasic, with all glomeruli show-
ing lesions of a similar age. This is in contrast to findings
in ANCA-positive systemic vasculitis, in which lesions
of different ages are often seen together. Lung histology
is rarely obtained, but examination of pulmonary tissue
can disclose alveoli containing red cells together with
hemosiderin-laden macrophages. Immunofluorescence
of lung tissue is technically difficult but can reveal inter-
mittent linear deposits of IgG along the alveolar base-
ment membrane.
Predisposing factors
Anti-GBM disease has been described in siblings and
two sets of identical twins, although discordant twins
also have been reported. As in other autoimmune dis-
eases, anti-GBM disease has been strongly associated
with the major histocompatibility complex (MHC). Sev-
eral serologic studies over the last 20 years have docu-
mented a strong association with the MHC class II gene,
HLA DR2 [13]. This association is consistent between
different Caucasoid populations and, overall, HLA DR2
is present in approximately 80% of cases. More recently,
genotyping studies have confirmed the association with
HLA DRB1*1501 and 1502 (corresponding to the sero-
logically defined HLA DR2 or DR15 genes) [14]. A
meta-analysis of more than 130 patients revealed a hier-
archy of associations, as observed in other autoimmune
diseases, with some genes conferring susceptibility and
others conferring resistance [15]. The strongest associa-
tion was with HLA DRB1*1501 but, when the effect of
this gene was excluded, subsequent analysis revealed an
increased frequency of DRB1*04 and DRB1*03 and a
decreased frequency of DRB1*07 and DRB1*01. Asso-
ciations with DQ alleles reflected the linkage disequilib-
rium with DR alleles; in particular, an increased fre-
quency of DQB1*06 (linked to DRB1*1501) was noted.
The meta-analysis also revealed that both inherited
DRB1 alleles had an effect on susceptibility, but that if
one of the alleles was DRB1*1501, the effect of the
second allele was either neutral (DRB1*04 and DRB1*03)
or protective (DRB1*07 and DRB1*01). Subsequent
functional studies showed that the protective alleles bound
the majority of peptides derived from the 3(IV)NC1
sequence with greater affinity than the major susceptibility
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allele, DRB1*1501 [16]. The authors suggest that protec-
tive alleles therefore might compete for peptide epitopes
with the susceptibility alleles. However, the precise mo-
lecular basis of these MHC associations remains to be
determined.
In X-linked Alport’s syndrome, which is due to muta-
tions in the 5 chain of type IV collagen, the supramolec-
ular organization of the 3, 4, and 5 chains in the
basement membrane is defective [17]. This alteration
leads to progressive abnormalities of the GBM, and of
basement membranes in the cochlea and eye, leading to
the clinical features of Alport’s syndrome. The absence
of expression of 5 (and the associated lack of 3 and
4) means that these molecules within a renal allograft
are regarded as foreign antigens [18]. The presence of
anti-GBM antibodies in the allografts of such patients
is relatively common, although clinical anti-GBM disease
is infrequent. The immune response in such cases is often
directed to the 5 chain, but also can be directed toward
the 3 or 4 chains. Although much rarer, mutations in
the 3 or 4 chain can lead to autosomally inherited
Alport’s syndrome [19], in which anti-GBM disease also
can occur in renal transplants.
Although a strong association exists between anti-
GBM disease and HLA DRB1*1501, this allele is present
in as many as one-third of individuals in white popula-
tions. It is therefore clear that additional factors, either
genetic or environmental, are required for disease ex-
pression. Environmental factors preceding diagnosis do
not necessarily drive the autoimmune response; instead
they might exacerbate pre-existing but unrecognized dis-
ease. Infectious agents have long been suspected as caus-
ative, for example, influenza in Goodpasture’s original
patient. Infection also might account for reports of clus-
tering of cases. However, no specific infectious agent has
yet been consistently linked to the disease. Exposure
to hydrocarbons has been associated with the onset of
symptoms, and case control studies have shown higher
levels of anti-GBM antibodies (at borderline levels) in
individuals exposed to inhaled hydrocarbons [20]. Ciga-
rette smoking has frequently been reported in associa-
tion with the development of disease [10], and relapse has
been linked to the onset of smoking [21]. One hypothesis
suggests that damage to the lung from infection, cigarette
smoke, or hydrocarbons exposes a cryptic epitope within
the alveolar basement membrane that triggers an auto-
immune response to 3(IV)NC1. However, no convinc-
ing evidence for this theory has surfaced, and it seems
more likely, at least for cigarette smoking, that the addi-
tional pulmonary insult allows or increases alveolar dam-
age in patients who already have circulating anti-GBM
antibodies. It has been suggested that, within the kidney,
urinary infection, lithotripsy, or pre-existing glomerulo-
nephritis likewise might reveal sequestered epitopes
within the GBM and lead to development of anti-GBM
disease in susceptible individuals. However, these condi-
tions are relatively common, while subsequent anti-
GBM disease is extremely rare.
Pathogenesis: Experimental models
I shall consider the role of animal models in illustrating
disease mechanisms and suggesting new approaches to
treatment. Two models of experimental anti-GBM dis-
ease are widely used. In experimental autoimmune glo-
merulonephritis (EAG), animals are immunized with
GBM or 3(IV)NC1 and subsequently develop an auto-
immune response that targets their own kidneys. In
nephrotoxic nephritis (NTN), animals are injected with
a heterologous antibody to GBM, which deposits in the
kidney and causes transient injury (the heterologous
phase). The animal then mounts its own immune re-
sponse to the foreign immunoglobulin, which acts as a
planted antigen on the GBM (the autologous phase).
This model can be made more severe by pre-immunizing
the animal with immunoglobulin from the species in
which the anti-GBM antibodies are raised, such that
immediate binding of the autologous antibody to the
planted foreign immunoglobulin occurs (the accelerated
or telescoped model of NTN). Although these models
have been developed in various species, most recent
studies have used either mice or rats.
Experimental autoimmune glomerulonephritis. Experi-
mental autoimmune glomerulonephritis has been diffi-
cult to induce reliably in mice. However, in one study,
the disease was strain-dependent and was linked to the
MHC and to a Th1 dominant pattern of cytokine expres-
sion [22]. Nephritis could be transferred by autoantibod-
ies (if T cell immunity in the recipient was intact), and by
mononuclear cells. It has also proved possible to induce
EAG in mice deficient in the inhibitory FcRIIB, in a
strain in which wild-type controls were resistant [23].
This suggests that the interaction of autoantibody with
Fc receptors on leukocytes is an important step in the
development of glomerular injury. In the FcRIIB knock-
out animals, activation of leukocytes via FcRI and
FcRIII was likely unopposed, although this has not
been proved in this model. More recently, mice geneti-
cally engineered to produce only human antibodies de-
veloped nephritis following immunization with recombi-
nant 3(IV)NC1. This disease was transferable by the
“human” anti-GBM antibodies produced by immunized
mice [24].
Experimental autoimmune glomerulonephritis in the
rat is also strain-dependent, and the most consistent
model is that induced in the Wistar-Kyoto (WKY) strain
[25, 26]. These animals develop severe crescentic glomer-
ulonephritis after immunization with crude GBM, and
the disease can be induced with purified or recombinant
3(IV)NC1 [27, 28]. Also, EAG can be transferred by
anti-GBM antibodies purified from the urine [29] or
eluted from the kidneys of nephritic animals (abstract;
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Reynolds J et al, J Am Soc Nephrol 12:639A, 2001). Wu
et al induced EAG in WKY rats using a denatured form
of recombinant 3(IV)NC1; in this system, glomerulo-
nephritis was associated with sensitized T cells but not
with antibody deposition [30]. The same group also dem-
onstrated that EAG could be transferred by CD4T cells
from nephritic rats, expanded in vitro by stimulation with
3(IV)NC1 [31]. No anti-GBM antibodies were detected
in the recipients. This experiment provides the best direct
evidence to date that T cells can cause autoimmune glo-
merulonephritis in mammals.
Taken together, these studies in EAG demonstrate
that anti-GBM antibodies as well as antigen-specific T
cells can be pathogenic under the right circumstances.
Furthermore, autoimmune responses to 3(IV)NC1, the
major antigen in human anti-GBM disease, are sufficient
to induce crescentic glomerulonephritis. It thus seems
likely that both humoral and cellular immunity can con-
tribute to glomerular damage in Goodpasture’s disease,
although direct evidence of cell-mediated injury in pa-
tients is lacking.
Before the T cell transfer experiments, the role of T
cells was implicated in EAG by the results of anti-T cell
therapy. For example, in the Brown Norway (BN) rat,
EAG can be inhibited by cyclosporine or by anti-CD4
antibodies [32]. In the WKY rat, blocking the major T
cell co-stimulatory pathways is also effective in pre-
venting disease. Separate studies have illustrated the role
of blocking the B7/CD28 pathway with soluble CLTA4-
Ig [33, 34] and blocking the CD40/CD40 ligand pathway
with anti-CD40L monoclonal antibodies (abstract; Rey-
nolds J et al, J Am Soc Nephrol 11:480A, 2000). Each
of these approaches reduced both anti-GBM antibody
production and severity of disease. A more direct role
for effector T cells in EAG is suggested by a study in
which anti-CD8 therapy did not affect circulating anti-
bodies but significantly reduced glomerulonephritis [35].
An alternative strategy is to induce antigen-specific toler-
ance, mediated by regulatory T cell subsets. The induc-
tion of mucosal tolerance, by administering oral GBM
prior to active immunization, was effective in reducing
T cell responses to GBM as well as the development of
glomerulonephritis [36]. Hopefully, one or more of these
approaches to T cell immunotherapy will prove effective
in human anti-GBM disease. Their clinical potential in
glomerulonephritis is supported by reports of the effec-
tiveness of anti-CD4 antibodies [37] and anti-thymocyte
globulin [38] in patients with systemic vasculitis.
Nephrotoxic nephritis. Nephrotoxic nephritis in mice
also can be difficult to induce. It seems to depend on
the quality of the “nephrotoxic serum,” typically raised
in sheep. The disease is strain-dependent, with Th1-dom-
inant strains developing crescentic glomerulonephritis in
the accelerated model of NTN [39]. Considerable use
has been made of knockout animals to demonstrate that
the disease depends on Th1-related cytokines such as
interleukin-12 (IL-12) and interferon  [40, 41], and can
be prevented by Th2-related cytokines such as IL-4 and
IL-10 [42]. The role of chemokines in murine NTN [43]
has been shown using mice deficient in monocyte chemo-
attractant protein-1 (MCP-1) or in chemokine receptors
[44], and by therapeutic studies blocking MCP-1 [45]. In
some mouse models of NTN, disease is critically depen-
dent upon CD4 T cells and can be induced in the
absence of functioning B cells [46]. The importance of
intrinsic renal cells in the pathogenesis of this model,
presumably due to antigen presentation to T cells, is
illustrated by the requirement for expression of MHC
class II on renal cells [47]. However, other experiments
in murine NTN support a major role for antibodies, as
the disease can be prevented by lack of the stimulatory
Fc receptors (FcRI and FcRIII) [48] and exacerbated
by lack of the inhibitory receptor FcRIIB [49]. Comple-
ment also appears to have an important role in the early
stages of NTN. Mice deficient in C3 and C4 are protected
from disease [50], whereas deficiency of complement-
regulating proteins worsens disease [51], as does defi-
ciency of C1q, probably by reducing clearance of glomer-
ular neutrophils [52]. Recently, the role of proliferation
of renal cells in murine NTN was demonstrated by a
study in which Gas6-deficient mice were protected from
disease [53].
Nephrotoxic nephritis in rats is similarly strain-depen-
dent. In several strains, crescentic nephritis can be achieved
using an accelerated model. However, in the WKY rat,
a single injection of nephrotoxic serum leads rapidly and
consistently to severe crescentic glomerulonephritis [54].
Nephrotoxic nephritis in the rat has been used to demon-
strate the effectiveness of different forms of anti-inflamma-
tory therapy [55], for example, blockade of inflammatory
cytokines, such as tumor necrosis factor (TNF), IL-1,
and migration inhibitory factor (MIF) [56, 57], or ad-
ministration of anti-inflammatory cytokines, such as IL-4
and IL-11 [58, 59]. The use of macrophages transfected
with adenovirus to express IL-4 has been reported as a
form of “gene therapy” [60]. The inhibition of chemo-
kines, for example, fractalkine or MCP-1, also has been
effective in preventing disease [61, 62]. An alternative
approach has been blockade of the adhesion molecules
important in leukocyte migration across the endothe-
lium. Blockade of both leukocyte function associated
molecule-1/intercellular adhesion molecule-1 (LFA-1/
ICAM-1) [63] and very late antigen-4/vascular cell adhe-
sion molecule-1 (VLA-4/VCAM-1) [64] interactions has
proved effective. The expression of several inflammatory
cytokines and adhesion molecules depends on transcrip-
tion factors such as nuclear factor-kappaB (NF-B). De-
coy oligodeoxynucleotides (ODN) to NF-B reduce glo-
merular inflammation in NTN [65]. The progression of
inflammation to scarring and renal failure can be inhib-
ited by approaches such as antibodies to very late anti-
gen-1 (VLA-1) [66].
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Fig. 2. Type IV collagen exists as a complex
supramolecular network. Three individual
3(IV) chains are interwoven to form a triple
helix, known as the protomer. The NC1 do-
mains are arranged in a head-to-head fashion
to form hexamers, and binding through the
7S domains completes the network structure.
Hexamers can be dissociated to form dimers
and monomers of NC1 domains, allowing
identification of 3(IV)NC1 as the autoanti-
gen (redrawn with permission from [72]).
As in EAG, it seems that there is a role for both anti-
GBM antibodies and T cells in different animal models
of NTN. Therapeutic studies, particularly in the rat, have
identified a number of targets for novel anti-inflamma-
tory therapy. Some of these are already being explored
in human disease. The use of anti-TNF antibodies is
currently being investigated in crescentic nephritis re-
lated to systemic vasculitis, and initial results seem prom-
ising (personal observations). Antibodies that block the
adhesion molecule CD18 have been successful in similar
patients [67]. It remains to be seen which of these novel
approaches, or which combination, will be most useful
in clinical practice.
Pathogenesis: Human anti-GBM disease
Anti-GBM disease is widely regarded as a good exam-
ple of an autoantibody-mediated disease. Much of the
research into pathogenesis therefore has involved studies
of the specificity and pathogenicity of anti-GBM anti-
bodies. More recently, the role of T cells has attracted
increasing interest, particularly in coordinating the auto-
immune response, but also in their potential as effector
cells (as shown in animal models). I shall briefly consider
what is known both about autoantibodies and T cells in
this disease.
Strong evidence indicates that anti-GBM antibodies
are directly pathogenic. The presence of these antibodies
is consistently linked to development of disease, and
antibody levels and severity of disease are broadly corre-
lated in some series [68]. Even more convincing, anti-
GBM disease recurs immediately in renal allografts if the
recipient still has circulating antibodies [1]. The classic
transfer experiments by Lerner et al, more than 30 years
ago, showed that antibodies eluted from the kidneys of
patients with anti-GBM disease could cause glomerulo-
nephritis when injected into squirrel monkeys [69].
The main target of these autoantibodies is the non-
collagenous domain (NC1) of the 3 chain of type IV
collagen [3(IV)NC1] [70, 71]. Figure 2 shows the local-
ization of 3(IV)NC1 in the GBM [72]. This molecule
is found together with 4 and 5 chains in certain special-
ized basement membranes, such as those of the kidney,
lung, choroid plexus, retina, and cochlea [73]. The GBM
also contains a separate network of 1 and 2 chains,
which are present in all vascular basement membranes.
Although sera from all patients recognize 3(IV)NC1,
sera from some patients also can bind less strongly to
other type IV collagen chains. Competition studies using
monoclonal antibodies to 3(IV)NC1 suggest that anti-
bodies from most patients bind to a common epitope
[74]. The precise localization of this epitope was subse-
quently determined using chimeric recombinant mole-
cules containing regions of 3(IV)NC1, together with
regions from the non-antigenic 1(IV)NC1 [75–77]. The
advantage of this approach is that the recombinant mole-
cule should maintain its three dimensional structure,
allowing recognition of conformational epitopes by anti-
GBM antibodies. Several groups have identified a major
epitope in the amino terminal region of 3(IV)NC1 and,
in one study, clinical outcome correlated with the level
of antibodies reactive with the construct containing 3
at the amino terminus [76]. Sera from some patients also
react less strongly with a site in the carboxyl region of
the molecule, and it is possible that certain autoantibod-
ies cross-react with these two homologous sites, whereas
others might recognize a conformational epitope formed
by a combination of both sites [78]. The major amino ter-
minal epitope has been mapped in detail by substituting
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Table 1. Treatment of anti-glomerular basement membrane (anti-GBM) disease
Initial
Plasma exchange Daily, 4 L exchange for 5% human albumin solution; use 300 to 600 mL fresh frozen plasma within 3 days of any
invasive procedure (e.g., biopsy) or in patients with pulmonary hemorrhage; continue for 14 days or until
antibody levels are fully suppressed; withhold if platelet count 70  109/mL, or hemoglobin 9 g/dL;
watch for coagulopathy, hypocalcemia, and hypokalemia
Cyclophosphamide Oral dosing at 2 to 3 mg/kg/day (round down to nearest 50 mg; reduce to 2 mg/kg/day in patients over
55 years); stop if white cell count 4  109/mL and restart at lower dose when counts 4  109/mL
Prednisolone Oral dosing at 1 mg/kg/day (maximum 60 mg); reduce dose weekly to 20 mg by week 6 and then more
slowly; no evidence for benefit of intravenous methylprednisolone and can increase infection risk (possibly
use if plasma exchange not available)
Prophylactic treatments Oral nystatin and amphotericin (or fluconazole) for oropharyngeal fungus infection; ranitidine or proton-pump
inhibitor for steroid-promoted gastric ulceration; low-dose cotrimoxazole for Pneumocystis carinii pneumonia
prevention; consider acyclovir as cytomegalovirus prophylaxis; consider calcium/vitamin D for prevention of
osteoporosis (but relatively short course of steroids)
Maintenance
Prednisolone Reduce dose slowly from 20 mg at 6 weeks; stop completely by 6 months
Cyclophosphamide Stop after 2 to 3 months; no further cytotoxic agents necessary
individual amino acids from the 1 to the 3 chain, and
9 residues critical for binding have been identified [79].
Hudson’s group recently described the quarternary orga-
nization of the Goodpasture antigen, in particular where
the major epitope is located within the NC1 hexamers
formed from cross-linked 3/5 heterodimers and 4/
4 homodimers [80].
Although anti-GBM disease is regarded as a proto-
typic autoantibody mediated disease, it is clear that T
cells also play a vital role. We know that T cell help is
required for the class-switched and highly specific anti-
body response, and T cell involvement also can be im-
plied from the strong MHC associations. In addition to
providing T cell help for antigen-specific B cells, effector
T cells might contribute directly to tissue injury. Both
CD4 and CD8 cells are found in affected glomeruli
[81], but their specificity has not yet been determined.
However, proliferation assays can detect T cells reactive
with 3(IV)NC1 in the circulation [82]. Interestingly, T
cells from normal individuals also show some prolifera-
tive capacity to the autoantigen in the absence of anti-
GBM antibodies. We have found that 3(IV)NC1 is
expressed in the thymus, so central tolerance should
be present, but some T cells presumably escape this
mechanism [83]. The finding of autoreactive T cells in
healthy individuals is not unique to Goodpasture’s dis-
ease and has been reported in other autoimmune condi-
tions.
The frequency of T cells specific for 3(IV)NC1 is
higher in patients than in controls [83]. This high fre-
quency in patients diminishes with time from disease
onset and reaches levels comparable to controls after a
number of years [83]. Our recent data suggest that this
reduction in frequency is accompanied by the emergence
of a CD4CD25 subset of regulatory T cells (abstract;
Salama AD et al, J Am Soc Nephrol 13:664A, 2002).
The epitopes of 3(IV)NC1 recognized by autoreactive
T cells have proved hard to define. The use of linear
peptides spanning the 3(IV)NC1 sequence has yielded
varying results. We have found it difficult to demonstrate
T-cell responses to such peptides, but others have re-
ported more promising findings using freshly isolated
cells from acute patients (abstract; Cairns LS et al, J
Am Soc Nephrol 11:473A, 2000). However, no dominant
T-cell epitope has been clearly defined.
Treatment and outcome
Untreated anti-GBM disease has an almost universally
poor outcome, with death from renal failure or lung
hemorrhage [1]. The use of steroids alone conferred little
benefit, but the introduction of combined treatment with
plasma exchange, cyclophosphamide, and corticosteroids
in the 1970s revolutionized the outcome in this disease
[84]. The rationale of this approach is that plasma ex-
change rapidly removes the pathogenic autoantibodies,
cyclophosphamide prevents further antibody synthesis,
and steroids act as a powerful anti-inflammatory agent.
A rapid reduction in anti-GBM antibody levels appears
to be necessary in view of the speed of glomerular dam-
age, and this cannot be achieved by drug therapy alone.
Only one small trial has compared plasma exchange with
drug treatment alone; this study demonstrated a more
rapid fall in anti-GBM antibodies and suggested a trend
toward a better outcome in the plasma exchange group
[85]. However, trials are difficult in such a rare disease,
and the improved outcome with plasma exchange re-
ported in many series makes it unlikely that further trials
will be attempted.
The treatment protocol used at the Hammersmith
Hospital is shown in Table 1. It is important to note the
intensive use of plasma exchange in this regimen, which
is generally successful in reducing anti-GBM antibody
levels to near normal within 2 weeks. Plasma exchange
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Table 2. Outcome of patients with Goodpasture’s disease
Renal recovery if
initial creatinine 600
Number of 1-year patient 1-year renal mol/L (6.6 mg/dL)
patients survival % survival % % treated patients Notes
Johnson et al [85] 17 94 45 0 Randomized prospective study of plasma exchange
Walker et al [86] 22 59 45 18 Australian single center; all plasma exchanged
Savage et al [68] 59 75 8.5 NAa Data from multiple British centers;
49 84 35 11 Hammersmith Hospital single center
Bouget et al [87] 14 79 29 0 French single center
Herody et al [88] 29 93 41 0 French single center; most plasma exchanged
Merkel et al [89] 35 89 40 6 Survival at time of analysis; all plasma exchanged
Daly et al [90] 40 — 20 0 All plasma exchanged
a NA, not available.
may be continued for longer if anti-GBM antibodies are
still detectable, in the presence of clinical evidence of
disease activity. In general, the disease does not relapse,
and immunosuppressive drugs can safely be discontinued
within a few months. Patients with both anti-GBM anti-
bodies and ANCA receive the same initial treatment as
those with pure anti-GBM disease, but the former then
receive maintenance immunosuppression, as used in
ANCA-positive systemic vasculitis. In our experience,
these “double-positive” patients behave the same as those
with isolated anti-GBM disease in their early response to
treatment (abstract; Levy JB et al, J Am Soc Nephrol
12:113A, 2001), although their subsequent course can be
more similar to that of ANCA-associated vasculitis.
In most recent series, 1-year patient survival in anti-
GBM disease is between 75% and 90%. However, renal
recovery is less common and depends on renal function
at the start of treatment. Several series show that most
patients starting treatment with a creatinine of less than
600 mol/L (6.6 mg/dL) will recover renal function, but
that recovery is rare in patients with an initial creatinine
of more than 600 mol/L (Table 2) [68, 86–90]. We
recently analyzed the Hammersmith Hospital series of
71 patients who received the regimen I described [9].
This was a severely affected cohort: 39 patients required
dialysis at presentation, 13 had an initial creatinine
greater than 500mol/L (5.7 mg/dL), and 19 had a creati-
nine of less than 500 mol/L. Pulmonary hemorrhage
was present in 62% and appeared commoner in younger
men. The patients who presented with creatinine less
than 500 mol/L had an excellent outcome at one year,
with 100% surviving and 95% retaining independent re-
nal function. Of those with a creatinine greater than
500 mol/L, but not requiring dialysis immediately, 83%
survived 1 year, and independent renal function was
maintained in 82% of survivors. However, the outcome
was not as good in dialysis-dependent patients, with 65%
surviving 1 year, and only 8% of those survivors retaining
Table 3. One-year outcome in treated anti-glomerular basement
membrane (anti-GBM) disease at Hammersmith Hospital
Number Patient survival % Renal survival %
Creatinine 500 19 100 95
Creatinine 500 13 83 82
Dialysis 39 65 8
Total 71 77 53
independent renal function (Table 3). Analysis of renal
outcome at 1 year, related to the percentage of crescents
on renal biopsy and to the initial serum creatinine,
showed that neither a high percentage of crescents nor
a high serum creatinine precluded recovery. However,
none of the patients with 100% crescents and undergoing
dialysis recovered independent renal function.
Long-term follow-up of these patients (Fig. 3) showed
that renal function was maintained over several years,
with 5-year renal survival of 94% for those presenting with
creatinine less than 500 mol/L, and 50% for those with
creatinine more than 500 mol/L. These results are of
particular interest, as they demonstrate that with inten-
sive treatment many patients with a serum creatinine
greater than 500 mol/L can recover renal function. To-
day’s case illustrates this outcome. We would argue that
all patients not established on dialysis should be offered
treatment with plasma exchange and immunosuppres-
sion. For those already on dialysis, the question of treat-
ment is more difficult. It could be argued, in view of the
low probability of recovery, that the risks of immunosup-
pression outweigh the potential benefit. However, for
younger patients with evidence of recent crescents on
biopsy, and who are not yet anuric, aggressive therapy
still could be considered. The presence of lung hemor-
rhage, which resolved in 90% of our patients, provides
a separate indication for intensive treatment, regardless
of the severity of renal disease.
Summary
Anti-GBM disease is due to an autoimmune response
to 3(IV)NC1, a major component of glomerular, alveo-
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Fig. 3. Long-term patient and renal survival in treated patients with
anti-GBM disease. (A ) Patient survival. The difference between pa-
tients with an initial creatinine concentration less than 500 mol/L and
the other groups was significant (P	 0.0055). (B ) Renal survival. Only
patients who did not require dialysis at presentation are included. The
difference between the two groups was not significant (redrawn with
permission from [9]).
lar, and other specialized basement membranes. The epi-
topes of 3(IV)NC1 recognized by autoantibodies have
been characterized at a molecular level, but T-cell epi-
topes are proving more elusive. Treatment with a com-
bined regimen of prednisolone, cyclophosphamide, and
plasma exchange has revolutionized the outcome of this
condition. Most patients presenting with a creatinine of
less than 500 mol/L (5.7 mg/dL) will recover long-term
independent renal function, as will about one-half of
patients presenting with a creatinine greater than 500
mol/L but not on dialysis. Renal recovery is rare in
patients requiring dialysis before treatment can be
started. Studies of experimental models of anti-GBM
disease suggest that anti-GBM antibodies as well as anti-
gen-specific T cells play a role in pathogenesis. The po-
tential of new approaches to treatment, including regula-
tion of the autoimmune response and modulation of
inflammatory mechanisms, has been demonstrated in
these models. The future challenge is to determine
whether these approaches can provide more effective
and safer treatment for patients with anti-GBM disease
or other types of crescentic glomerulonephritis.
QUESTIONS AND ANSWERS
Dr. John T. Harrington (Division of Nephrology,
Tufts-New England Medical Center, Boston, Massachu-
setts): Has the incidence of anti-GBM disease decreased
since influenza vaccination has become standardized
across western Europe and the United States? Also, why
do you think your patients did so well, particularly those
who had a serum creatinine above 500 mol/L?
Prof. Pusey: Your first question relates to the role of
infection in causing or triggering this disease. It seems
likely that Goodpasture’s original patient had influenza,
and there are several reports of clusters of cases, sug-
gesting infection as a cause. There have also been a few
studies relating infections, such as influenza, to develop-
ment of disease. I do not know of any rigorous case con-
trolled studies, and I am unconvinced that any specific
infectious disease has been linked to anti-GBM disease.
I think it is a little too early to say whether the incidence
has changed following introduction of the influenza vac-
cine. The various series of rapidly progressive glomerulo-
nephritis that I have reviewed in the literature appear to
show a pretty constant incidence of anti-GBM disease. In
most studies, it is probably the second most important
cause to ANCA-positive rapidly progressive glomerulone-
phritis (RPGN). The incidence does not seem to be de-
creasing; on the other hand, it does not seem to be rising
either. I do not think the flu vaccine has altered the inci-
dence very much.
In response to your second question about outcome,
in the series I presented, the majority of patients with a
creatinine of over 500 mol/L but not on dialysis recov-
ered [9]. I think recovery might relate to the intensity
of the plasma exchange regimen we use and the speed
with which we use it, because, in many other published
series, plasma exchange is used at a lower volume per
exchange and at a lower frequency. For example, some
centers might use 2.5 or 3.0 L two or three times a week.
Even if they are attempting to use it daily, they probably
do not because it is time-consuming for the nursing staff,
and it involves a lot of equipment and extra effort. So
there are drawbacks to plasma exchange inasmuch as it
is difficult to deliver. By keeping our regimen at 14 daily
4 L exchanges, our practice differs from that in other
series. I cannot tell you whether that is the only differ-
ence, but it is one difference that is apparent.
Dr. Indranil Dasgupta (Birmingham Heartlands
Hospital, Birmingham, U.K.): Is there any justification
for using plasma exchange in a patient with anti-GBM
disease who requires dialysis at presentation but who
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has no evidence, clinical or otherwise, of pulmonary
hemorrhage?
Prof. Pusey: If a patient has any evidence of lung
hemorrhage, then that is a separate indication for plasma
exchange. Lung hemorrhage rapidly kills you if un-
treated, but it responded in 90% of patients in our study
[9]. Hemorrhage is not always obvious on a chest radio-
graph, and the patient does not always cough up blood;
a falling hemoglobin disproportionate to the degree of
renal failure might alert you. If so, then you can perform
the KCO, a sensitive way of detecting lung hemorrhage
[10]. If no lung hemorrhage is present and the patient
already is on dialysis, then you have to think very hard. If
the patient has severe renal failure but is not on dialysis, I
would argue that you should treat, and our results sup-
port that argument, even though previous thoughts were
that you should not treat patients with a creatinine of
over 600 mol/L. After dialysis is initiated, you need to
tailor your decision to each individual. For a young pa-
tient who has recently started dialysis, particularly if the
biopsy shows acute changes and some normal glomeruli,
you would discuss the risks and benefits of treatment.
In an elderly patient, who is less able to tolerate treat-
ment, and in whom there is extensive scarring on biopsy,
you should not treat. Thus, there would be exceptions
in which you might treat dialysis-dependent patients, and
that depends on their clinical state and renal biopsy.
Prof. John Feehally (Department of Nephrology,
Leicester General Hospital, Leicester, U.K.): Charles, as
you rightly pointed out, we are past the 25th anniversary
of the treatment regimen, and we are all still doing ex-
actly the same thing. My question is about how you
would test new treatment. You have a treatment that
works and saves lives, and the things that you might
want to add as new treatments will be quite potent, such
as anti-T-cell therapy or anti-TNF therapy. How are you
going to add them without increasing toxicity? How are
you going to decide what you leave out, and how are
you going to judge success?
Prof. Pusey: I will answer by referring to our practice
in systemic vasculitis first. In systemic vasculitis, we use
the same drugs, cyclophosphamide and prednisolone.
In advanced cases, as you know, we also use plasma
exchange, which might be superior to methylpredniso-
lone in this situation. We have investigated anti-TNF
antibodies as additional therapy in patients who present
with systemic disease and renal involvement, with clinical
features like those in the CYCAZAREM trial [91]. We
then compared the rate of response with anti-TNF ther-
apy, using the Birmingham Vasculitis Activity Score
(BVAS), renal function, and markers of disease, with a
well-studied cohort in CYCAZAREM. So we are using
a historic comparator before designing a randomized
controlled trial. We also have used anti-TNF antibodies
in patients who are initially in remission, and then start
to relapse, or who show evidence of “grumbling” disease,
and we add anti-TNF as the only change in therapy.
In Goodpasture’s disease, we cannot study relapse
because it very rarely relapses, but we could add anti-
TNF antibodies to the existing therapy at presentation
and look at the outcome compared with historic series
from our own and other units. I think a historic compari-
son is probably the only way to go initially. If this ap-
proach appeared not to cause any harm, or even to show
a possible benefit, then my aim would be to try and
remove the more harmful parts of the current protocol
successively—to reduce, for example, the high dose of
steroids initially, or to limit the dose of cyclophospha-
mide. So the answer to your question is that it would be
very difficult to do a trial when you have patients with
a severe disease and a treatment that works. However,
I am keen that we try and if our experience in vasculitis
is very positive, that might convince us use a similar
approach in anti-GBM disease.
Prof. Andrew Rees (Department of Medicine and
Therapeutics, Institute of Medical Sciences, Aberdeen,
U.K.): Charles, you alluded in passing to a very interest-
ing group of patients who had linear staining of the GBM
with essentially negative anti-GBM ELISA, but positive
anti-GBM antibodies by a much more sensitive assay,
the biosensor assay. Can you tell us more about the
phenotype of those patients? Did they have severe ne-
phritis and, in particular, is there any hint of a predomi-
nant role of the T cells in that particular group?
Prof. Pusey: These patients, in fact, were fairly typical:
they all had severe nephritis. They had linear deposits
of immunoglobulin as detected by our renal pathologist,
but the standard ELISA assays were negative. At the
time, we treated them according to the immunofluores-
cence, because we were convinced by the clinical features
and by the pathologic findings. Only when we subse-
quently went on to develop the biosensor assay did we
look at these patients in more detail and find that they
had detectable anti-GBM antibodies. They were toward
the lower end of the limit that we detected on biosensor
in known positive patients, but they were clearly differ-
ent from all of the controls. I did not look specifically
to see whether there were many more T cells in their
glomeruli. The immune response in those patients might
have been a little more tipped toward T cells and a little
less toward antibodies.
Prof. Rees: There of course are ancient examples from
the 1970s of negative immunofluorescence on the first
biopsy of a patient with crescentic nephritis, followed
by positive immunofluorescence on the second biopsy
shortly afterwards.
Prof. Pusey: Yes, you are right, and this supports your
suggestion for a predominant role for T cells at an early
stage in some cases.
Dr. Jeremy Hughes (Centre for Inflammation Re-
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search, University of Edinburgh Medical School, Edin-
burgh, U.K.): You mentioned clustering. It is certainly
striking when you see it, because recently in Edinburgh
we have had two unrelated patients who presented with
this disease and who live on the same street just by
a railway track and a gas station. Do you think that
environmental agents, apart from infection, might play
a role either in initiation or pathogenesis of this disease?
My second question is whether there is a human equiva-
lent of the Lewis rat, that is, someone who makes anti-
bodies but is resistant to getting disease?
Prof. Pusey: The environmental question has been
widely addressed. As you know, a number of cases have
developed after prolonged and excessive hydrocarbon
exposure. A case control study in the north of England
looked at workers in a factory who were either exposed
to petroleum-based oils or not [20]. Those with consider-
able exposure appeared to have higher levels of anti-
GBM antibodies, although usually not outside the nor-
mal range. So I think hydrocarbons indeed might be
important. Smoking also might play a role and, by dam-
aging the alveolar basement membrane, might release
sequestered antigens and lead to an increased incidence
of disease. However, making etiologic links is quite diffi-
cult, because it is also clear that smoking might just
increase the degree of lung damage in those who already
have anti-GBM antibodies. I would suggest that this is
the mechanism in most of these cases; if you have anti-
GBM antibodies circulating, then smoking will make the
alveolar capillaries more permeable or activate macro-
phages, and the disease becomes manifest. In short, there
are associations between anti-GBM disease and infec-
tion, hydrocarbons, and smoking. I am not absolutely con-
vinced that these are proven etiologic factors. Clearly,
something in the environment must be involved, because
around 25% of us are walking around with DR2, yet
only a very small percentage of us will get Goodpasture’s
disease. So the MHC associations alone do not go any-
where near to explaining why you get the disease, and
other genetic and environmental factors presumably
contribute to its development.
With regard to the rats, obviously the WKY strain
is exquisitely sensitive; some other rats make a minor
response, Brown Norway for example, and others appear
to be completely resistant, like the Lewis. As you may
know, we currently have a breeding program to study
genetic linkages with disease in the WKY strain, and
we found that F1 animals, that is, cross of Lewis and
WKY, are totally resistant, suggesting that resistance is
dominant. You can cross WKY rats with the F1 rats and
make a backcross (BC1) generation. In these backcross
animals, a proportion of them are susceptible, and a
proportion of them are resistant. We have bred a large
number of these, and we are doing a genome-wide link-
age analysis to try and identify genetic factors over and
above the MHC. With regard to humans, a few patients
have presented with hematuria and lung hemorrhage and
do not appear to have developed crescentic nephritis, at
least within the time they have been followed before
treatment. These people might possess other genes that
are protective. I would not be at all surprised if humans
show a range of inflammatory responses to the deposi-
tion of a certain amount of antibody, but I do not have
results to support this suggestion. Maybe if we can track
down the susceptibility genes in the rats, we can use
these as candidate genes in the patients.
Dr. Ajay Singh (Renal Division, Brigham and Wom-
en’s Hospital, Boston): My question has to do with the
issue of patients with Alport’s syndrome developing
what appears to be anti-GBM disease, particularly in the
context of a second transplant. How do you treat this
disease in the context of transplant immunosuppression,
and what strategies do you use to prevent it?
Prof. Pusey: The first thing is to be aware of the possi-
bility and to get the diagnosis of Alport’s right. Then
you can monitor anti-GBM antibody production care-
fully. As you know, the production of anti-GBM antibod-
ies and their deposition in the kidneys of patients with
Alport’s after a first allograft is not particularly common,
maybe 10% to 20%. Severe nephritis is very uncommon.
If we were giving a patient with Alport’s a first allograft,
we would monitor circulating anti-GBM antibodies regu-
larly, make sure we did fluorescence or peroxidase stud-
ies on any renal biopsies, and consider the possibility of
Goodpasture’s disease carefully. If it looked as if this
were developing, we would treat the patient using the
strategy I previously outlined. In patients developing
disease after a second graft, the disease seems to be
much more aggressive. We have seen two such patients,
tried to treat them, and failed in both. It looks like the
stimulus of a second large dose of what is essentially an
allo-antigen is just too much. For the benefit of those
who do not look after this sort of patient, most cases of
Alport’s are X-linked and missing 5 chains of type IV
collagen, but they can get an immune response not only
to 5 but also to 3 and 4, which are not incorporated
correctly in the collagen network. There are rare auto-
somally inherited cases of Alport’s in which the patient
is defective in 3 or 4 chains; anti-GBM disease in the
grafts also has been reported [19]. So anti-GBM disease
in Alport’s patients who have undergone renal trans-
plantation is not typical, because it involves a response
to 5 in many cases, which is not the case in the native
kidney of patients with Goodpasture’s disease. If it oc-
curs in a second graft, which is what you are asking, it
is very difficult to treat, and I would be interested to hear
whether anyone has successfully treated these patients.
Dr. Singh: Have you treated patients with plasma-
pheresis before they get the second graft?
Prof. Pusey: We have not. As it happens, they have
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been referred to us with evidence of disease following
a second graft, and they have been treated rapidly and
aggressively but have not responded.
Prof. Rees: We have attempted to prevent recurrence
in one patient using the sort of regimens that people
have used for preventing graft rejection in patients who
have pre-formed antibodies to the graft, and we have
failed. We used a combination of plasma exchange plus
cytotoxic drugs.
Prof. Caroline Savage (MRC Centre for Immune Reg-
ulation, The Medical School, University of Birmingham,
Birmingham, U.K.): Charles, you put up a very good
case for T cells as effector cells in anti-GBM disease. In
fact, the current effective therapy that you outlined is
geared to antibody removal and against the B cell. If
you are really contemplating the introduction of anti-
T-cell therapy in this disease, are you not in danger of
removing the good regulatory T cells?
Prof. Pusey: I think you are. If CD8 T cells were
involved in humans, which I think we have yet to demon-
strate, then perhaps an anti-CD8 antibody in addition
to conventional therapy would be a good approach. Stan-
dard immunosuppressive therapy, including cyclophos-
phamide, affects both B and T cells and clearly induces
a response. But targeting pathogenic T cells specifically
would be a good idea. I think one aspect of your question
is that if you wanted to target activated T cells, they
would be CD4 and CD25, as they express CD25
as part of their activation state. These might be the bad
guys. The same phenotype, CD4 and CD25, is pres-
ent on some regulatory subsets, so you would perhaps
want to target the bad ones but end up damaging the
good ones. Ideally, you would spare the good ones, or
perhaps even stimulate their activity. It is not a straight-
forward situation. On balance, in the acute phase of the
disease, you would want to make sure you targeted auto-
aggressive T cells as hard as possible but did not inhibit
development of regulatory T cells, which could be gener-
ated later. At present, we do not know enough about
the phenotypes of the different regulatory subsets to be
able to do this.
Dr. Alan Salama (Renal Division, Brigham and
Women’s Hospital, Boston): We looked at CD25 regu-
latory cells in alloresponses in patients who had received
anti-IL-3 therapy, and such therapy does not seem to
preclude development of regulatory cells. So, partly, I
believe there is a clone size effect. If you get rid of
enough autoreactive T cells, the regulatory cells can then
emerge. My second point relates to Andy Rees’ question
about T cells in patients who did not have detectable
antibodies. We only studied one such patient in terms
of T-cell responses. Actually, he had a very high T-cell
response, so it might be useful to look at patients who
do not have circulating antibodies to see whether they
are a subset of Goodpasture’s patients who have a more
T-cell–mediated disease.
Dr. Christopher Winearls (Renal Unit, Oxford Rad-
cliffe Hospital, Oxford, U.K.): Charles, your case presen-
tation includes a rather intriguing comment that, on renal
biopsy, the interstitium contained a dense mononuclear
cell infiltrate. Did the biopsy reveal antibody binding to
the tubular basement membrane? Does tubular injury,
perhaps related to deposition of antibody on the tubular
basement membrane, affect renal function? Also could
the treatment, which was remarkably effective in this
case considering the glomerular injury, in fact be a result
of dealing with tubular injury rather than glomerular
injury?
Prof. Pusey: That is a valid point. Indeed, in many
studies of anti-GBM disease, one also finds deposition
of IgG on the tubules. In fact, immunoperoxidase stain-
ing in the case I showed did demonstrate both glomerular
and tubular deposition of immunoglobulin. It appears
to be the distal tubules that express the Goodpasture
antigen, rather than the proximal tubules; nonetheless,
antibody is deposited in the tubules. This deposition
might, for example, recruit macrophages or other in-
flammatory cells from the circulation and be responsible
for the tubulointerstitial infiltrate. However, I think the
tubulointerstitium can become inflamed via other mech-
anisms, one of which is possibly ischemic, because you
can imagine that the crescentic glomeruli are not letting
a lot of blood through to the interstitium. Another mech-
anism might be the flow of inflammatory mediators, such
as cytokines, along the tubules, which could stimulate
or injure the tubular cells from the luminal side. Third,
as you saw in the high-power view of the biopsy specimen
(Fig. 1B), when this disease is very severe within the
glomerulus, you see breaks in Bowman’s capsule, fol-
lowed by direct spillover of cells outside the capsule.
Often the interstitial inflammation is strongly periglom-
erular, as it was in this patient. I can therefore give you
a number of potential mechanisms whereby tubulointer-
stitial nephritis might develop, although I cannot tell you
exactly by which mechanism it occurs. I do think it is
very important in determining prognosis of the disease,
although we have not specifically examined it in our
series.
Dr. Charles Tomson (Renal Unit, Southmead Hospi-
tal, Bristol, U.K.): You mentioned that anti-GBM disease
is monophasic, and that sets it apart from many of the
other autoimmune diseases that we see. Is there anything
in the human or animal studies that tells us why it is
monophasic?
Prof. Pusey: Not directly, but I suspect one explana-
tion is that the antigen responsible is “relatively” cryptic.
The antigen is held within the NC1 hexamer within the
basement membrane of the kidney and the lung. It is
not immediately accessible to antigen-presenting cells or
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T cells, and it is not usually exposed in an inflammatory
milieu. It might be exposed, however, under certain cir-
cumstances. For example, lung infection can reveal alve-
olar antigen, and renal infection or obstruction can reveal
kidney antigen. Indeed, several instances of anti-GBM
disease have developed after either lithotripsy or ob-
struction of the kidney. It could just be that a human
with a severe chest infection is like a rat immunized
with GBM in Freund’s adjuvant. If you allow antigen
presentation in an inflammatory situation, you might
stimulate an immune response. That state of stimulation
then resolves, because either the infection gets better
or we stop doing lithotripsy, and there is no longer an
additional push of antigen into the immune system. Reg-
ulatory mechanisms can then come into play. I think
that might be the case in Goodpasture’s. The antigenic
stimulus overcomes natural tolerance mechanisms for a
while, and then the body tips back into equilibrium. It
is the mechanisms by which that happens, and how we
can push the human from activation of these T cells to
tolerance, that we need to learn more about. Perhaps in
auto-immune responses involving other antigens, such
as DNA or histones in lupus, antigens might be more
widespread, accessible, or prone to being presented.
Prof. Peter Mathieson (Renal Unit, Southmead Hos-
pital): Could you speculate on how much of the effective-
ness of plasma exchange is due to the removal of circu-
lating mediators rather than to the removal of the
pathogenic antibody itself? Second, I have a practical
question. In an acute renal failure practice, anti-GBM
disease is probably the only disease in which a delay of
a day or two makes a major difference to outcome, and
yet it is a very rare disease. How can we balance these
two things? Should we be sending serum samples from
our referring hospitals to you or someone else who can
do an anti-GBM assay so that we can deal with the delay
that inevitably occurs in this country, and I guess in other
health care systems, in transferring patients to a center
where they can be managed?
Prof. Pusey: In reply to your first question, we and
others have also used immunoabsorption using protein
A [92]. We have used it in one or two patients who, for
various reasons, could not receive human blood prod-
ucts; their disease was quite advanced, and they did not
recover despite rapid removal of antibody. Swedish
groups have used protein A immunoabsorption more
extensively in Goodpasture’s disease, and I’ve seen iso-
lated reports of patients who did not initially respond to
plasma exchange but then did better with immunoabs-
orption [92]. The rationale is that you can remove immu-
noglobulin more quickly using protein A immunoabsorp-
tion. Despite these promising reports, we have not started
using immunoabsorption as our major therapeutic strat-
egy, because plasma exchange also removes inflamma-
tory mediators, for example, complement components
and coagulation factors. By not removing them and fo-
cusing on the antibody, you might lose some of the thera-
peutic effect. We have become slightly trapped by the
success of the current regimen. Much as I would like to
be doing selective or even specific immunoabsorption, I
think we are not yet in a position to do that.
With regard to your second question, I think that as
part of your acute renal failure screen, in the presence
of suspicious circumstances like proteinuria or hematu-
ria, an urgent anti-GBM assay should be performed.
Because the disease is treatable if diagnosed early, I
think this approach is justified.
Prof. David Oliveira (Division of Renal Medicine, St
George’s Hospital Medical School, London): With re-
spect to the mechanism of the protective effect of certain
MHC alleles, there are, as you hinted, other mechanisms
apart from determinant capture. For example, do you
have any information on the restriction of the regulatory
population? Or do you have any information on mecha-
nisms of the dominant nonresponsiveness in your F1
hybrid rats?
Prof. Pusey: Those are good questions, but I do not
have a good answer yet. Antigen-specific regulatory T
cells can be detected in patients following stimulation
with 3(IV)NC1, but we do not know how the protective
or susceptibility MHC alleles influence their develop-
ment. In our rat models, it is clear that the MHC is one
factor, because in WKY rats from different sources, with
either a RT1-l or RT1-k haplotype, those with RT1-l get
severe disease, whereas those with RT1-k get much less
severe disease. In our breeding program, we have
matched the MHC such that both the WKY and the
Lewis rats are RT1-l, so no difference in MHC exists
across the parental strains. The difference in respon-
siveness in F1 animals is therefore not directly related
to MHC genes in that particular cross; it must depend
on other genes influencing immune or inflammatory re-
sponses [93]. I agree that the MHC will have effects
other than that on peripheral antigen presentation and
could be involved in molding the T-cell repertoire. Our
studies of infiltrating glomerular T cells in EAG show
restricted T-cell receptor gene usage, and further work
on this might be informative (abstract; Habib A-MN et al,
J Am Soc Nephrol 13:172A, 2002). For example, we could
look at different crosses and see whether the same CDR3
sequences are used.
Dr. William Nelson (Renal Unit, Belfast City Hospi-
tal, Belfast, Northern Ireland): Charles, can you charac-
terize the small number of patients who relapse?
Prof. Pusey: One of our patients who relapsed was a
young man who was incapable of stopping smoking for
any significant period. He did in fact give up smoking
for a time after he came off intensive care during the
initial illness, but then he started again. He had at least
two episodes of relapse with lung hemorrhage and ne-
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phritis, the first of which was successfully treated using
the same regimen as before and which resulted in his
stopping smoking. The final episode, when he started
smoking again, led to severe lung hemorrhage, which he
survived, then severe nephritis, which did not respond,
and he ended up on dialysis.
The second patient who relapsed worked as a hair-
dresser and regularly used volatile aerosol hairsprays.
We considered suggesting that she change her profes-
sion, but this was not practical because she was depen-
dent on her job. She had a minor relapse, changed the
sprays she used, and did not have another relapse. She
is still well and under regular follow-up several years
later. I do not know whether these anecdotes have any
bearing on the incidence of relapse, but in both cases
there was a potential environmental factor.
Dr. Nelson: A patient of ours relapsed 18 months
after an initial acute episode. He had negative anti-GBM
titers on our conventional ELISA assay, linear IgG on
the biopsy, and a positive ANCA. Has this been your
experience?
Prof. Pusey: Briefly, double-positive patients are ini-
tially similar to those with anti-GBM disease, that is,
they are unlikely to come off dialysis. However, the con-
tinuing management of those patients should be along
the lines of that for systemic vasculitis. Although the
anti-GBM antibody goes away, and nearly always stays
away, the ANCA tends to recur. Many of our patients,
having recovered from their initial anti-GBM and
ANCA-positive disease, are then treated with mainte-
nance therapy as for other ANCA-positive patients. This
is entirely consistent with the literature saying that pa-
tients with ANCA are liable to relapse [94]. If ANCA
is the primary factor, it also begs the question whether
ANCA-induced damage to the GBM releases GBM anti-
gens in an immunogenic fashion and leads to develop-
ment of anti-GBM disease. It would be interesting to
look at the serum of your patient using a biosensor to
see whether he has low levels of anti-GBM antibodies
as well as ANCA.
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